We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Vifor Pharma's Phase III study on its ...

FREMONT, Calif., Sept. 3, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with ...

olaparib targets prostate cancer mutations Calcium-based binders, however, are associated with greater odds of all-cause mortality versus sevelamer. Phosphate-binder therapy does not reduce mortality ...

NEW YORK, Nov 30 (Reuters) - An experimental drug being developed by Keryx Biopharmaceuticals Inc to lower abnormally high levels of phosphate in the blood of patients with advanced kidney disease ...

Thrombotic occlusion of blood vessels, which leads to myocardial infarctions, strokes and venous thromboembolisms, is the major cause of death in the western hemisphere. Therefore, it is of critical ...